The bill strengthens federal biosecurity by clarifying who is regulated, standardizing screening, and investing in technical and governance capacity—trading off faster, more coordinated risk reduction for new compliance costs, privacy and access concerns, enforcement risks, and possible centralization challenges.
Researchers, providers, and purchasers get a clearer federal framework (who is regulated, which agencies lead, and pathways for certification), reducing regulatory ambiguity for DNA synthesis and related equipment.
Short-term gene‑synthesis screening, prioritized mitigation of high‑risk sequences, and improved threat analysis reduce the risk that malicious actors obtain or create pandemic-capable agents.
Expedited review pathways, NIST technical standards, and secure test environments speed legitimate research and improve screening accuracy and interoperability across providers.
Small businesses, biotech firms, and research labs face substantial new compliance costs and administrative burdens (screening, audits, red‑teaming, conformity assessments) that could slow work or raise prices.
Broad definitions of covered providers plus procurement rules (federally funded entities required to buy only from compliant suppliers) may restrict access to suppliers, raise costs, and limit options for students, educators, and niche researchers.
Customer and order screening and the collection of sensitive data create privacy and commercial‑confidentiality risks for researchers and buyers, with potential for breaches despite exemptions and security rules.
Based on analysis of 6 sections of legislative text.
Requires regulated screening, conformity assessments, and standards for nucleic acid synthesis providers, creates a governance sandbox, and mandates an OSTP-led federal biosecurity assessment and implementation plan.
Requires regulation and federal coordination to screen orders for synthetic nucleic acids, set conformity and auditing systems for providers, create technical standards and a biotech governance "sandbox," and produce a federal assessment and implementation plan to modernize biosecurity and biosafety oversight. The bill directs Commerce (NIST), the Secretary of Commerce, and the OSTP Director to develop standards, testing, enforcement mechanisms, and an annual reporting process to reduce misuse risk while supporting innovation.
Official title: Require the Secretary of Commerce to promulgate regulations to improve nucleic acid synthesis security, and for other purposes.
Introduced January 29, 2026 by Thomas Bryant Cotton · Last progress January 29, 2026